Following a full submission
AWMSG advice |
||
| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED OCTOBER 2007. Refer to TA129: Bortezomib monotherapy for relapsed multiple myeloma for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | bortezomib (Velcade®) | |
| Formulation | 3.5 mg powder for solution for injection | |
| Reference number | 65 | |
| Indication | Treatment of progressive multiple myeloma in patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy |
|
| Company | Janssen-Cilag Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Full | |
| Status | Superseded | |
| AWMSG meeting date | 08/06/2005 | |
| Ratification by Welsh Government | 19/08/2005 | |
| Date of issue | 19/08/2005 | |
| NICE guidance | ||